Malignant tumors of the esophagus in the Czech Republic
Authors:
M. Duda 1,2; L. Adamčík 2; L. Dušek 3; M. Škrovina 2; T. Jínek 2
Authors place of work:
II. chirurgická klinika FN a LF UP Olomouc
1; Chirurgické oddělení nemocnice a Komplexního onkologického centra Nový Jičín
2; Institut biostatistiky a analýz Masarykova univerzita Brno
3
Published in the journal:
Rozhl. Chir., 2012, roč. 91, č. 3, s. 132-140.
Category:
Review
Summary
Introduction:
Data analysis of the incidence, mortality and basic data regarding therapy of esophageal cancer in the Czech Republic and determining possible ways to improve the current situation.
Material and methods:
Analysis was performed using data obtained from the Czech National Cancer Registry and from the Registry of Thoracic Procedures from the Section of Thoracic Surgery of the Czech Surgical Society. Analysis of specialized literature provided generally accepted risk factors for the development of esophageal cancer.
Results:
Esophageal cancer represents 0.7% of all solid malignant tumours in the Czech Republic (1.1% in males and 0.2% in females). During 1977 to 2008, the incidence increased from 2 to 5.4 cases per 100.000 inhabitants and mortality from 1.9 to 4.1 cases per 100.000 inhabitants. In absolute numbers, the incidence was 561 cases (5.4 per 100.000 inhabitants) in 2008. Absolute mortality rate was 452 deaths (4.3 per 100.000 inhabitants) and absolute prevalence (number of patients living with cancer or with its medical history) was 791 subjects(7.6 per 100.000 inhabitants). When compared to international data, the incidence in the Czech Republic is the 84th highest in the world and 17th highest in Europe (mortality rates are at the 85th place in the world and the 18th place in Europe). In the Czech Republic, the highest incidence is in the Moravian-Silesian and Zlin regions (6.1 per 100.000), the lowest in the Plzeň (4.2) and Vysočina (4.1) regions. The average age at the time of diagnosis is 62 years in males and 68 years in females, the maximum incidence is between 55 and 69 years in males and between 58 and 79 years in females. Upon diagnosis, advanced stages of the disease predominate. In 2008, 28% of the detected esophageal cancer cases were stage I and II disorders, 60 % were stage III and IV disorders, and in 12% of the cases the stage was not determined. In the treated patient group, the five-year survival rate was 15.5% in total, based on an analysis of data from 2004 – 2007. The five-year survival was 30% in stage I and II diosease cases, 12% in stage III disorders and 2% in stage IV cases. When comparing the analysis of data from 2004 to 2007 with the analysis of data from 2000 to 2003, there is a 10% improvement in stages I and II and a 4% improvement in stage III disorders . According to the Thoracic Surgery Registry of Thoracic Procedures data covering the period 2007 to 2010, thoracic procedures are performed at 19 to 22 surgical departments, esophageal resections are performed at 13 to 14 surgical departments, but only in 8 to 9 of these departments is the frequency of such procedures more than 10 operations per year. At the authors’ department, 53 esophageal resections have been performed in the past five years with a 3.8% postoperative mortality rate and a 23 % total postoperative morbidity rate. Forty-nine percent of the cases were adenocarcinomas.
Conclusion:
Based on its incidence in our population, esophageal cancer can be considered an unfrequent tumour. This analysis shows regions of the Czech Republic with higher incidence and the most at-risk age group in males. Significant risk factors for squamous cell cancer such as smoking and alcohol consumption have already been previously identified; in adenocarcinoma it is primarily Barrett’s esophagus. Other risk groups include patients with achalasia and with strictures after corrosion injury to the esophagus. Acceptable treatment results may only be achieved in patients with less severe stages of the disease and it would therefore be appropriate to actively search for such patients in at-risk regions and among the risk groups as part of the preventive programs. To date, universally accepted guidelines for monitoring of such patients have not been defined. Surgical treatment is a highly specialized domain of thoracic surgeons focused on esophageal surgery and patients should be concentrated in specialized centres.
Key words:
esophageal cancer – epidemiology – treatment – results
Zdroje
1. Národní onkologický registr (NOR) České republiky, Systém pro vizualizaci onkologických dat ( SVOD) www. cba.muni.cz/svod.
2. Dušek L, editor. Czech cancer care in numberes. 2008-2009. Praha, Grada Publishing; 2009.
3. Schüttzner J. Registr hrudních výkonů v České republice 2007, 2008, 2009 a 2010. Praha, nepublikované sdělení 2011.
4. Duda M, Žaloudík J, Ryska M, Dušek L. Chirurgická léčba solidních nádorů v České republice. Rozhl Chir 2010;89(10):588–593.
5. Neoral Č, Aujeský R, Král V, Klein J, Bohanes T, Vrba R, Koranda P. Technika získání sentinelových uzlin u tumorů v oblasti distálního jícnu a žaludku. Rozhl Chir 2005;84(6):307–309.
6. Polanecký O, Pazdro A, Tvrdoň J, Teršíp T, Šmejkal P, Smejkal M, Hladík P, Pafko P. Paliativní ošetření karcinomu jícnu – naše zkušenosti. Rozhl Chir 2006;85(4):186–189.
7. Pafko P, Pazdro A. Radikální léčba karcinomu jícnu (abstrakt). Bulletin HPB (Časopis české hepato-pankreato-biliární společnosti) 2008;16(1–2):14–16.
8. Tvrdoň J, Haruštiak T, Pazdro A, Teršíp T, Pafko P. Stenty – paliativní a kurativní ošetření jícnu. Sedmileté zkušenosti chirurgického pracoviště. Rozhl Chir 2008;87(7):355–359.
9. Dostalík J, Guňková P, Martínek L, Richter V, Guňka I, Mazur M, Mitták M. Optimální miniinvazivní přístup při náhradě jícnu žaludkem. Rozhl Chir 2009;88(8):422-424.
10. Neoral Č, Aujeský R, Král V. Náhrady jícnu tlustým střevem – zkušenosti se 109 případy. Rozhl Chir 2010;89(12):740–745.
11. Aujeský R, Neoral Č, Král V, Vrba R, Vomáčková K. Videoasistovaná resekce jícnu pro karcinom – desetileté zkušenosti. Rozhl Chir 2010;89(12):746-749.
12. Šerý Z, Duda M, Korhoň M, Gazárek F, Nitsche R. Chirurgie jícnu a kardie. Čas Lék Čes 1976;115(31):954–958.
13. Šerý Z, Duda M, Dlouhý M, Gazárek F, Roček V. Naše zkušenosti s léčbou nádorů jícnu. Plzeň lék Sborn. 1983;Suppl.47:29–33.
14. Duda M, Dlouhý M, Roček V, Gryga A, Janda P, Šerý Z. Die chirurgische Behandlung des Ösophauskarzinoms. Acta Univ Palacki Olomouc Fac Med 1989;123:177–188.
15. Dlouhý M, Duda M, Roček V, Janda P, Lovečková J. Komplexní diagnostika a strategie chirurgické léčby karcinomu jícnu. Klinická onkologie 1993;2:51–55.
16. Köcher M, Dlouhý M, Neoral Č, Gryga A, Duda M. První zkušenosti s potahovaným spirálním Z-stentem domácí produkce v léčbě inoperabilních procesů jícnu. Čes Gastroent Výž 1997;51(1): 20–23.
17. Köcher M, Dlouhý M, Neoral Č, Gryga A, Duda M, Buriánková E, Aujeský R. Paliativní léčba inoperabilních stenóz jícnu stenty: dlouhodobé výsledky, komplikace. Rozhl Chir 1998;78(1):51–55.
18. Köcher M, Dlouhý M, Neoral Č, Buriánková E, Gryga A, Duda M, Aujeský R. Esophageal Stent with Antireflux Valve for Tumore Involving the Cardia: Work in Progress. JVIR 1998;9(6):1007–1010.
19. Bollschweiler E, Hölscher AH. Deutliche Zunahme des Adenokarcinom sim Ösophagus. Dtsch Artztebl 2000; 97:1896–1900.
20. Corley DA, Buffler PA. Oesophageal and gastrin cardia adenocarcinomas: Analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30: 1415–1425.
21. Giuli R, Siewert JR, Couturier D, Scarpignato C, editors. Barretts Esophagus. Paris, John Libbey Eurotext 2003.
22. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alkohol and socioeconomic status and adenocarcinoma of the esofagus and gastric cardia. J Nat Cancer Inst 1997;89:1277–1284.
23. Kollárová H, Máchová L, Horáková D, Janoutová G, Čížek L, Janout V. Rizikové faktory u karcinomu jícnu. Čs Gastroent Hepatol 2008;62(2):79–83.
24. Lagergren J, Bergström R, Nyrén O. Assotiation between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130(11):883–890.
25. Brown LM, Silverman DT, Pottern LM, et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alkohol, tabacco and socioeconomic factors. Cancer Causes Control 1994;5:333–340.
26. Chang F, Syrjanen S, Shen Q, et al. Human papillomavirus involvement in esophageal carcinogenesis in the high-incidence area of China. Study of 700 cases by screening and type-specific in situ hybridization. Scand J Gastroenterol 2000;35:123–130.
27. Oę Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease–clinical implications and management. Aliment Pharmacol Ther 1999;13:117–127.
28. Liu SF, Shen Q, Dawsey SM, et al. Esophageal balon cytology and subsequent risk of esophageal and gastrin cardia cancer in a high-risk Chinese population. Int J Cancer 1994;57:775–780.
29. Stein HJ and panel of experts. Esophageal cancer: screening and surveillance. Results of a consensus conference. Dis Esoph 1996;9(Suppl 1):3–19.
30. Siewert JR, Stein HJ, Lordick F. Ösophaguskarcinom. In: Siewert JR, Rothmund M, Schumpelick V, Herausgeber. Praxis der Visceralchirurgie. Onkologische Chirurgie. 2.Auflage. Heidelberg, Springer Verlag 2006.
31. Dimick JB, Wainess R, Upchurch G, et al. National trends in outcomes for esophageal resection. An Thorac Surg 2005;79:212–218.
32. Wenner J, Zilling T, Bladstroom A, Alvegard TA. The influence of surgical volume on hospitál mortality and 5-year survival for carcinoma of the eosophagus and gastric cardia. Anticancer Res 2005;25:419–424.
33. Wouters MW, Wijnhoven BP, Karim-Kos HE et al. High-volume versus low-volume for esophageal resection for cancer: the essentials role of case mix adjustments based on clinical data. Ann Surg Oncol 2008;15:80–87.
34. Metzger R, Bollshweiler E, Vallböhmer D et al. High volume centers fo esophagectomy: what is the number needed to achive low postoperative mortality? Dis esophagus 2004;17:310–314.
35. Stavrou EP, Smith GS, Baker DF. Surgical outcomes associated with oesophagectomy in New South Wales: an investigation of hospital volume. J Gastrointest Surg 2010;14:951–957.
36. Verhoef C, van de Weyer R, Schaapveld M, et al. Better survival in patiens with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologist. Ann Surg Oncol 2007;14:1678–1687.
37. Thompson AM, Rapson T, Gilbert FG, Park KGM. Hospital volume does not influence long-term survival of patiens undergoing surgery for oesophageal or gastric cancer. Br J Surg 2007;94: 578–584.
38. Dimick JB, Pronovost PJ, Cowan JA Jr, Lipsett PA. Surgical volume and quality of care for esophageal resection: do high-volume hospitals have fewer complications? Ann Thorac Surg 2003;75:337–341.
Štítky
Surgery Orthopaedics Trauma surgeryČlánok vyšiel v časopise
Perspectives in Surgery
2012 Číslo 3
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Restoration of active foot extension following peroneal nerve palsy
- Retrogastric bronchogenic cyst
- Osteosynthetic material breakage in patients treated with DHS for proximal femoral fracture
- Malignant tumors of the esophagus in the Czech Republic